
|Articles|April 27, 2020
Cerner Provides Access to De-Identified Patient Data for COVID-19 Research
Advertisement
Cerner Corporation is offering select U.S. health systems and academic research centers complimentary access to critical de-identified COVID-19 patient data to help fight the pandemic. The offering will provide eligible health care researchers free access to Cerner’s COVID-19 data set to support epidemiological studies, clinical trials, and medical treatments related to COVID-19. The de-identified patient data secured on Cerner HealtheDataLab, powered by Amazon Web Services Inc. will include COVID-19-related demographics to help track spread and surge, underlying illnesses and chronic conditions, lab results, clinical complications, and more that could help drive medical decisions.
For more information, click
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Beyond Patient Centricity: What Rare Disease Research Gets Right
2
FDA Reaffirms GCP Standards Amid Growing Concerns Over Foreign Clinical Trial Data
3
What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale
4
The Unquantified Value of RBQM: Reduced Rework, Data Integrity, and Inspection Readiness
5



